INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Cytokines in the bone marrow of multiple myeloma patients activate Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathways in tumor cells and promote tumor growth, survival, and drug resistance. INCB16562 was developed as a novel, selective, and orally bioavailable small-molecule inhibitor of JAK1 and JAK2 markedly selective over JAK3. The specific cellular activity of the inhibitor was demonstrated by its potent and dose-dependent inhibition of cytokine-dependent JAK/STAT signaling and cell proliferation in the absence of effects on Bcr-Abl-expressing cells. Treatment of myeloma cells with INCB16562 potently inhibited interleukin-6 (IL-6)-induced phosphorylation of STAT3. Moreover, the proliferation and survival of myeloma cells dependent on IL-6 for growth, as well as the IL-6-induced growth of primary bone marrow-derived plasma cells from a multiple myeloma patient, were inhibited by INCB16562. Induction of caspase activation and apoptosis was observed and attributed, at least in part, to the suppression of Mcl-1 expression. Importantly, INCB16562 abrogated the protective effects of recombinant cytokines or bone marrow stromal cells and sensitized myeloma cells to cell death by exposure to dexamethasone, melphalan, or bortezomib. Oral administration of INCB16562 antagonized the growth of myeloma xenografts in mice and enhanced the antitumor activity of relevant agents in combination studies. Taken together, these data suggest that INCB16562 is a potent JAK1/2 inhibitor and that mitigation of JAK/STAT signaling by targeting JAK1 and JAK2 will be beneficial in the treatment of myeloma patients, particularly in combination with other agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633
Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
Nicholson, S. E., Willson, T. A., Farley, A., Starr, R., Zhang, J., Baca, M., Alexander, W. S., Metcalf, D., Hilton, D. J., & Nicola, N. A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.2.375 · Cited by 407 · cited 1×
“JAKs can also be aberrantly activated by either mutation, such as the JAK2V617F mutation that is found in myeloproliferative disease (MPD) or epigenetic inactivation of negative regulators such as SOCS1/3 and SHP-1 [17, 18 ].”
BackgroundHematopoietic cytokine receptor signaling
Baker, S. J., Rane, S. G., & Reddy, E. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210757 · Cited by 256
Suematsu, S., Matsusaka, T., Matsuda, T., Ohno, S., Miyazaki, J., Yamamura, K., Hirano, T., & Kishimoto, T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.1.232 · Cited by 227 · cited 1×
“In mice, constitutive expressionofIL-6—aJAK-dependentcytokine—issufficienttoinduceplasmacytomas [ 6 ,34]; conversely, IL-6 knockout mice are resistant to tumor induction in an induced model of B-cell neoplasms [5].”
BackgroundAnalysis of Signal Transducer and Activator of Transcription 3 (Stat 3) Pathway in Multiple Myeloma
Quintanilla-Martinez, L., Kremer, M., Specht, K., Calzada-Wack, J., Nathrath, M., Schaich, R., Höfler, H., & Fend, F. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64278-2 · Cited by 93
Cited by
JAK/STAT signaling in hematological malignancies
Vainchenker, W., & Constantinescu, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.347 · Cited by 528
Multifunctional dendritic polymers in nanomedicine: opportunities and challenges
Khandare, J., Calderón, M., Dagia, N. M., & Haag, R. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15242d · Cited by 418
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 338
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Maude, S. L., Tasian, S. K., Vincent, T., Hall, J. W., Sheen, C., Roberts, K. G., Seif, A. E., Barrett, D. M., Chen, I.-M., Collins, J. R., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415448 · Cited by 289
Self-citationUnraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Hu, Y., Dong, Z., & Liu, K. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02949-5 · Cited by 268
Metadata
- Authors
- Li, J., Favata, M., Kelley, J. A., Caulder, E., Thomas, B., Wen, X., Sparks, R. B., Arvanitis, A., Rogers, J. D., Combs, A. P., Vaddi, K., Solomon, K. A., Scherle, P. A., Newton, R., & Fridman, J. S.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 12
- Issue
- 1
- Pages
- 28-38
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W1575204077
- Cited by
- 79
- References
- 7
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.